Drugs / DEG6498
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07244835 | Nov 2025 → Dec 2028 expected | cancer | Degron Therapeutics Co. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEG6498 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07244835 ↗ |
| Modality | Other / unclassified | “DEG6498 is an orally bioavailable molecular glue drug that potently induces the degradation of human antigen R (HuR).” NCT07244835 ↗ |
| Route | Oral | “Participants who are treated in this study will receive DEG6498 orally once a day” NCT07244835 ↗ |